RxDoctor Payments Data

Nixi Cat, DO

Family Medicine · Elmira, NYNPI 1154828010

Payments from drug & device makers

$1,205in general payments, 2019–2025

Across 49 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$582
  • Novo Nordisk$176
  • Biohaven Pharmaceutical Holding Company Ltd.$116
  • Sumitomo Pharma America, Inc.$96
  • Averitas Pharma Inc.$46
  • Lilly USA, LLC$36
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$1,17598%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,205 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$5,233
Medicare patients
16
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$36,567
Xtampza ErOxycodone Myristate14$12,923
EliquisApixaban17$10,779
FarxigaDapagliflozin Propanediol13$10,689
SymbicortBudesonide/Formoterol Fumarate18$5,018
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen128$4,805
Oxycodone Hcl123$3,016
Albuterol Sulfate HfaAlbuterol Sulfate49$1,656
Vilazodone Hcl17$1,609
Potassium Chloride34$999
Naloxone Hcl15$899
Acetaminophen-CodeineAcetaminophen With Codeine19$863
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$822
Gabapentin38$603
Ondansetron OdtOndansetron21$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$36,56739 claims
AstraZenecaFarxiga, Symbicort$28$15,70731 claims
PfizerEliquis$22$10,77917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →